


# Starting Dose

## Prescribe EPOGEN® Starting Dose Based on Your Patient's Weight

The rate of rise in Hb (Hct) is dose-dependent<sup>12</sup>




Data is from Phase I/II clinical trial. (Eschbach et al, *Am J Kidney Dis*, 1987)

See package insert for complete dosing information. As the hematocrit approaches 36%, reduce the dose of EPOGEN®. The EPOGEN® package insert recommends a target Hb (Hct) of 10 to 12 g/dL (30% to 36%).

- Patients who weigh more generally require higher starting doses than smaller patients, within the recommended EPOGEN® starting dose range of 50 to 100 U/kg TIW
- EPOGEN® doses that may be adequate to elicit a timely and appropriate Hb response in some patients may not be adequate in other patients due to differences in bone marrow sensitivity<sup>13</sup>

Achieve Hb levels in the NKF-K/DOQI™ target range of 11 to 12 g/dL\* in a clinically appropriate time frame



Hct increases in anemic dialysis patients measured in points per day and points per 2-week period. Classified by the different EPOGEN® doses administered IV TIW. (EPOGEN® [Epoetin alfa] prescribing information, Amgen)

- In the Phase III clinical trial, 97.4% of patients achieved a mean Hct of 35% within 18 weeks with adequate EPOGEN® doses<sup>14</sup>